obinutuzumab + naptumomab estafenatox + durvalumab

This drug is a **combination therapy** of three agents: - **Obinutuzumab** is an anti-CD20 monoclonal antibody routinely used to deplete B cells and here employed as pre-treatment to suppress anti-drug antibody formation against naptumomab estafenatox[1][3]. - **Naptumomab estafenatox (Anyara, Nap)** is a recombinant fusion protein combining an antibody fragment targeting the 5T4 tumor-associated antigen and a mutated superantigen, designed to enhance T-cell activation and direct immune response to tumor cells expressing 5T4[1][5]. - **Durvalumab (Imfinzi, MEDI4736)** is a monoclonal antibody immune checkpoint inhibitor targeting PD-L1, which blocks the PD-1/PD-L1 pathway and restores antitumor immunity[1][5]. This combination is being studied for safety and preliminary anticancer activity in advanced or metastatic solid tumors, with particular focus on preserving naptumomab plasma levels, maximizing immune effect, and reducing anti-drug antibody formation. The protocol involves obinutuzumab pre-treatment, followed by naptumomab estafenatox and durvalumab administration.

Other names

obinutuzumabnaptumomabNapnaptumomab estafenatoxdurvalumabMEDI4736MEDI-4736MEDI 4736